Journal of Clinical Endocrinology & Metabolism, Vol 70, 920-924, Copyright © 1990 by Endocrine Society

ARTICLES

Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?

BJ Riis, C Christiansen, JS Johansen and J Jacobson
Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, Denmark.

Recent studies have shown that treatment with the LHRH agonist nafarelin gives symptomatic and objective relief to women with endometriosis. Such a treatment, however, results in increased bone turnover and loss of bone mass. In the present study 17 women with endometriosis were treated with 400 mg nafarelin combined with 1.2 mg norethisterone (NET) for 6 months, followed by 6 months with only 1.2 mg NET. The data were compared to data from a previously published study of 9 women treated for 6 months with 400 mg nafarelin alone, followed by 6 months without treatment. In the group treated with nafarelin plus NET the biochemical parameter of bone resorption (fasting urinary hydroxyproline) remained virtually unchanged, compared to a highly significant increase in the nafarelin-treated group. Estimates of bone formation (serum alkaline phosphatase and plasma bone Gla protein) increased in the nafarelin plus NET group, but to only a minor extent compared to those in the nafarelin group. In addition, bone mineral in the forearm, the spine, and the total skeleton remained virtually unchanged in the group treated with nafarelin plus NET, compared to the bone loss of 2-6%/6 months in the nafarelin group. We conclude that addition of NET to nafarelin treatment of endometriosis seems to have a bone-sparing effect.

This article has been cited by other articles:

				J. Enriquez, A. E. Lemus, J. Chimal-Monroy, H. Arzate, G. A Garcia, B. Herrero, F. Larrea, and G. Perez-Palacios The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites J. Endocrinol., June 1, 2007; 193(3): 493 - 504. [Abstract] [Full Text] [PDF]

				H. Fernandez, C. Lucas, B. Hedon, J.L. Meyer, J.M. Mayenga, and C. Roux One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial Hum. Reprod., June 1, 2004; 19(6): 1465 - 1471. [Abstract] [Full Text] [PDF]

				J. H. Tobias, S. Clarke, K. Mitchell, S. Robins, H. Amer, and W. D. Fraser Analysis of the Contribution of Dydrogesterone to Bone Turnover Changes in Postmenopausal Women Commencing Hormone Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1194 - 1198. [Abstract] [Full Text]

				J. E. Compston Sex Steroids and Bone Physiol Rev, January 1, 2001; 81(1): 419 - 447. [Abstract] [Full Text] [PDF]

				K. K. Miller and A. Klibanski Amenorrheic Bone Loss J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1775 - 1783. [Full Text]

				J. S. Finkelstein, A. Klibanski, A. L. Arnold, T. L. Toth, M. D. Hornstein, and R. M. Neer Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34): A Randomized Controlled Trial JAMA, September 23, 1998; 280(12): 1067 - 1073. [Abstract] [Full Text] [PDF]

				E. A. Amama, M. Taga, and H. Minaguchi The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 333 - 338. [Abstract] [Full Text]

				J. S. Finkelstein, A. Klibanski, E. H. Schaefer, M. D. Hornstein, I. Schiff, and R. M. Neer Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency N. Engl. J. Med., December 15, 1994; 331(24): 1618 - 1623. [Abstract] [Full Text]